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Summary
Of the many inherited Charcot-Marie-Tooth peripheral
neuropathies, type 2D (CMT2D) is caused by dominant
point mutations in the gene GARS, encoding glycyl
tRNA synthetase (GlyRS). Here we report a dominant
mutation inGars that causes neuropathy in themouse.
Importantly, both sensory and motor axons are af-
fected, and the dominant phenotype is not caused by
a loss of the GlyRS aminoacylation function. Mutant
mice have abnormal neuromuscular junction mor-
phology and impaired transmission, reduced nerve
conduction velocities, and a loss of large-diameter pe-
ripheral axons, without defects in myelination. The
mutant GlyRS enzyme retains aminoacylation activity,
and a loss-of-function allele, generated by a gene-trap
insertion, shows no dominant phenotype in mice.
These results indicate that the CMT2D phenotype is
caused not by reduction of the canonical GlyRS activ-
ity and insufficiencies in protein synthesis, but instead
by novel pathogenic roles for the mutant GlyRS that
specifically affect peripheral neurons.
Introduction
Charcot-Marie-Tooth neuropathies (CMTs) are inherited
disorders of the peripheral nervous system (PNS). As
a group, they represent the most common genetic dis-
eases of the PNS, affecting approximately 1 in 2500 peo-
ple (Skre, 1974). Broadly, the diseases are separated
into demyelinating neuropathies (type 1), diagnosed by
reduced nerve conduction velocities, and axonal neu-
ropathies (type 2), arising from defects intrinsic to the
neuron.
Recent advances in human genetics and mouse
models have identified several disease genes and have
begun to explain the pathogenic mechanisms of some
forms of CMT (Berger et al., 2002; Shy et al., 2002), in-
cluding genes that act autonomously in Schwann cells
to alter myelin and cause type 1 neuropathies (Aguayo
et al., 1977; Hayasaka et al., 1993; Roa et al., 1993) and
genes involved with the axonal cytoskeleton or vesicle
trafficking, causing type 2 neuropathies (Jordanova
et al., 2003; Verhoeven et al., 2003).
Interestingly, two forms of CMT are caused by muta-
tions in aminoacyl tRNA synthetases, the enzymes that
*Correspondence: robert.burgess@jax.orgcovalently link amino acids onto their cognate tRNAs
and thereby establish the genetic code relationship
between amino acids and the nucleotide triplets that
encode them. Mutations in tyrosyl-tRNA synthetase
(TyrRS) cause dominant intermediate CMT type C
(DICMT-C) (Jordanova et al., 2006). These mutations
partially lack enzymatic activity, and the mechanism is
proposed to be a haplo-insufficiency, in which protein
synthesis is impaired and the resulting peripheral neu-
ropathy presumably reflects the high demands for
translation in the peripheral nervous system.
Mutations in the GARS gene, encoding glycyl tRNA
synthetase (GlyRS), cause CMT2D, a slowly progressive
neuropathy that affects primarily the distal extremities
(Antonellis et al., 2003). Interestingly, the human GARS
mutations causing CMT2D are all dominant, are all sin-
gle amino acid changes, and are not clustered in a partic-
ular domain of the enzyme. There is only one gene en-
coding GlyRS in the mammalian genome, and it gives
rise to both the mitochondrial and cytosolic proteins
(Mudge et al., 1998; Shiba et al., 1994; Turner et al.,
2000). As a dimerizing enzyme with an essential function
and no close homologs for redundancy, mutations in
GARS are similarly good candidates for a haploinsuffi-
ciency or a dominant-negative mechanism. However,
this has not been demonstrated, and an alternative pos-
sibility is that the mutant forms of GlyRS are assuming
new functions that lead to the loss of peripheral axons.
Though GlyRS aminoacylation activity is required in all
cells, CMT2D affects only the peripheral nervous system
and begins only after young adulthood. Motor neurons
are affected in all cases, but the involvement of sensory
neurons is variable and not well defined clinically. Thus
CMT2D is also diagnosed as distal spinal muscular atro-
phy V (SMA-DV) (Antonellis et al., 2003; Del Bo et al.,
2006; Dubourg et al., 2006; Sambuughin et al., 1998;
Sivakumar et al., 2005), and the cause of the variable
presentation is unknown.
We have identified a mouse model of CMT2D, devel-
oped through the positional cloning of a mutation caus-
ing overt neuromuscular dysfunction. The mutation is an
amino acid alteration in Gars, the mouse ortholog of the
CMT2D geneGARS. Phenotypically, the mice have a se-
vere axonal neuropathy of both sensory and motor
axons. Biochemical and genetic analyses indicate that
the phenotype is not caused by a haplo-insufficiency
or a dominant-negative loss-of-function mechanism,
thus the mutant protein must be assuming a novel path-
ogenic role in peripheral neurons.
Results
Identification of a Gars Mutation in Mice
We have identified a mouse mutation causing overt neu-
romuscular dysfunction by 3 weeks of age (see video
at http://www.jax.org/media/burgess/burgess.html) and
dramatically shortening average life span. The mutation,
designatedNmf249, was identified in the Neurosciences
Mutagenesis Facility at The Jackson Laboratory in 2004
(www.jax.org/nmf/). The inheritance pattern indicated a
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716Figure 1. Positional Cloning of Nmf249
(A) Affected mice were scored based upon overt neuromuscular dysfunction and significantly reduced body weight, evident by 3 weeks of age
(p < 0.0001). Body weights 6 SD are shown for affected and unaffected littermates from nine different matings (n = 6–13 mice per time point).
(B) Analysis of 103 N2 mice defined the genetic interval containing the mutation as 1.9 mb between D6MIT354 and D6Mit384, which contains the
Gars gene.
(C) Sequencing Gars revealed a change of CC to AAATA (highlighted in the chromatogram) in the portion of the transcript encoded by exon 7,
changing proline 278 to a lysine and tyrosine. The beginning of intron 7 is shaded gray.
(D) The altered proline is highly conserved and is only six amino acids from a glycine altered in one allele of GARS identified in human CMT2D
patients (green G in human sequence). Conserved amino acids are in red; the altered proline is highlighted yellow.
(E) The change in the Gars coding sequence does not alter mRNA expression levels based on Northern analysis using b-actin as a loading
standard.dominant mutation, with 23/56 offspring affected when
the original carrier was bred to wild-type C57BL/6J
(B6) males (see Experimental Procedures). The mutation
is most often lethal by 6–8 weeks of age, with only 10 of
254 affected mice surviving longer than 6 months in an
inbred B6 colony.
The mutation arose in a B6 background and was map-
ped in an N2 backcross to BALB/cByJ (BALB). Affected
mice were scored based upon smaller size (Figure 1A)
and the overt neuromuscular phenotype. No change in
the mutant phenotype was observed in B6/BALB F1
mice, suggesting that the phenotype is not modified
by loci in the BALB genetic background. A genome
scan was performed on 16 affected and 11 unaffected
N2 mice, and linkage was established with D6Mit188 at
32.5 cM on chromosome 6. Analysis of 76 additional
N2 recombinants narrowed the interval to 1.9 mb be-tween D6Mit354 and D6Mit384 (Figure 1B), a region
with shared synteny to human chromosome 7p15.
This interval contains Gars, the mouse ortholog of the
CMT2D gene, GARS, in humans. Gars is a 17 exon gene
encoding a 729 amino acid protein. Given the neuromus-
cular phenotype of Nmf249, we sequenced the Gars
cDNA in affected mice and identified a change in the
open reading frame. A replacement of CC with AAATA
changes the proline at residue 278 to tyrosine and lysine
(Figure 1C) without affecting the rest of the open reading
frame. Proline 278 is conserved throughout eukaryotic
phylogeny (Figure 1D), extending even to bacteria. The
amino acid is near the catalytic domain 2 of the protein
and is close in the primary sequence to an amino acid af-
fected in one human disease allele. The mutation does
not affectGarsmRNA levels, as shown by Northern anal-
ysis (Figure 1E).
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ogy and Denervation in GarsNmf249/+ Mice
(A) Control neuromuscular junctions (NMJs)
in the gastrocnemius muscle of P36–P37
mice show normal branching and mature
morphology, with the motor nerve terminal
(green) completely overlapping the acetyl-
choline receptors (AChRs) on the muscle
(red). (B) In GarsNmf249/+ mice, the motor neu-
rons still branch within the muscle; however,
NMJs have an abnormal morphology, and nu-
merous partially innervated (arrowheads) and
completely denervated (arrows) postsynaptic
sites are seen. (C) At higher magnification, the
nerve terminal is directly above the AChRs on
the muscle, and the synapse has assumed
a ‘‘pretzel-like’’ morphology in control mice.
(D) NMJs from GarsNmf249/+ mice never
achieve a normal morphology, and a ‘‘best
case’’ junction is shown. (E) Many junctions
show regions of postsynaptic specialization
that are not overlain by the nerve terminal.
(F) In some cases, only a small portion of
the postsynaptic receptor field is covered
by the nerve terminal. Note the small diame-
ter of the axon. (G) Receptor fields with no as-
sociated nerve are also evident. The abnor-
malities in innervation at P36–P37 are
degenerative, as no differences are seen be-
tween control (H) and GarsNmf249/+ (I) NMJs
at P7. (J) Quantification of the NMJs at P36–
P37 revealed that in GarsNmf249/+ gastrocne-
mius muscles, only 48.8% 6 11.4% of the
NMJs were completely overlapped by a nerve
terminal (as in [D]), while 31.3% 6 6.1% were
partially overlapped (as in [E] and [F]), and
19.9% 6 5.9% had no nerve in close proxim-
ity (as in [G]). The scale bar in (I) represents
172 mm for (A) and (B) and 14 mm for (C)–(I).
Values in (J) are mean 6 SD.Neuromuscular Junction Defects
in GarsNmf249/+ Mice
Since CMT2D causes a distally accentuated loss of mo-
tor axons, we examined the neuromuscular junctions of
affected mice. In mature control mice, motor neurons
entered the muscle and branched, with each muscle fi-
ber contacted by a single motor nerve terminal. The
nerve terminal completely overlapped the postsynaptic
receptor field on the muscle (Figures 2A and 2C). In
GarsNmf249/+ mice, the general pattern of innervation
was comparable to controls; nerves entered the muscle
and branched. However, by P36–P37, many partially in-
nervated and completely denervated junctions were ap-
parent (Figures 2B and 2D–2G). This process was de-
generative, since NMJs in control and mutant P7 mice
were indistinguishable (Figures 2H and 2I). The occu-
pancy (the extent of overlap between the pre- and post-
synaptic structures) of NMJs was determined at each
age. At P7, NMJs were fully occupied in both control
and GarsNmf249/+ mice (99.0% 6 1.2% and 99.4% 6
0.5%, respectively, n = 5 mutant and 5 littermate control
mice, 100 NMJs examined per muscle). However, at
P36–P37 the control mice maintained full occupancy
(99.25% 6 1.5%), while GarsNmf249/+ mice showed
31.3%6 6.1% partially occupied and 19.9%6 5.9% de-nervated NMJs (Figure 2J, n = 4 mutant and 4 littermate
control mice).
The results shown in Figure 2 and reported above
were obtained in the gastrocnemius muscle, and similar
results were obtained in the neighboring soleus and
plantaris (data not shown). Interestingly however,
a much milder phenotype was seen in the triangularis
sterni, an axial muscle on the medial ribcage (see
Figure S1 in the Supplemental Data available online), in
which 92.25% 6 2.0% of NMJs were fully innervated
and 7.5% 6 1.7% were partially innervated. In sum,
these results indicate a severe degenerative process in
the motor nerve terminals and are consistent with
length-dependence pathology, with more distal mus-
cles of the hind limb having a more severe neuropathy.
Functional analysis of muscle contractile properties
evoked by tetanic nerve stimulation revealed failure
in production and maintenance of muscle force in
8-week-old mice. The failure to maintain force corre-
sponded to decreased electromyogram amplitude, sug-
gesting synaptic transmission failure at higher frequen-
cies (Figures 3A and 3B). Although analysis revealed
reduced muscle weights (Figure S2), even when normal-
ized for body weight, this was attributable to smaller
fiber size, and no pathological changes were seen
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718Figure 3. Muscle Contractile Properties and
Nerve Conduction in GarsNmf249/+ Mice
(A) The medial gastrocnemius muscle was
assayed for tetanic force generation with 80
Hz stimulation of the nerve. Control muscles
show tetanic fusion and maintain force for
1.2 s of stimulation (top trace). Mutant mus-
cles show tetanic fusion, although with
much less force generated, but fail to main-
tain force (bottom, gray trace).
(B) The failure to maintain force corresponds
to a significant decrement in the integrated
electromyogram (EMG) amplitude (p < 0.01
at pulses 48–57 and pulses 87–96). For
(A) and (B), four GarsNmf249/+ mice (mean
age 56 6 20 days) and four Gars+/+ mice
(mean age 55 6 12 days) were analyzed.
(C) Electromyogram traces showing latencies
in response to distal and proximal nerve stim-
ulation revealed a decreased compound
muscle action potential amplitude and in-
creased latency in the GarsNmf249/+ mice.
The scale bars correspond to 1 ms (horizon-
tal) and 1 mV (vertical).
(D) Quantification of the increased distal la-
tency indicated a significant decrease in
nerve conduction velocity (p < 0.01).
Values in (B) and (D) are means 6 SD.histologically, nor was a reduction in fiber number ob-
served in young animals, although the kinetics of the iso-
metric twitch contractions were slowed.
Nerve conduction velocities (NCVs) were also de-
creased by 60% in the affected mice, falling from 24.4 6
5.1 m/s in control animals to 10.4 6 1.2 (p < 0.01) in the
sciatic nerve of GarsNmf249/+ mice (Figures 3C and 3D)
(three mutant and three control animals measured at
P34). Although the defects in distal motor-axon morphol-
ogy and synaptic connectivity with minimal muscle pa-
thology are consistent with an axonal/type 2 neuropathy,
the reduced nerve conduction velocity is clinically diag-
nostic of demyelinating/type 1 CMTs and has been re-
ported as unaffected or moderately reduced in CMT2D
patients (Del Bo et al., 2006; Ionasescu et al., 1996; Siva-
kumar et al., 2005).
Reduced Axon Diameter without Myelination Defects
in GarsNmf249/+ Sciatic Nerves
We investigated possible causes of reduced NCV in the
GarsNmf249/+ mice, including decreased axonal diameter
and demyelination in the peripheral nerve. We also ex-
amined the distance between nodes of Ranvier on
teased axons, since shortened internodal distances
(INDs) decrease the efficiency of saltatory conduction
and have been reported as a cause of reduced NCV in
periaxin null mice (Court et al., 2004).
The sciatic nerve was examined at P7, and the nerves
from control and mutant animals were indistinguishable
by histological staining (Figures 4A and 4B). Importantly,
the largest myelinated axons of the GarsNmf249/+ nerves
were equivalent in size to the largest axons of control
nerves (Figures 4C). However, a small but significant
shift in the distribution of axon diameters (p < 0.001,
K-S test) was found, including a population of smaller-
diameter axons with comparatively thick myelin in the
mutant nerves (circled, Figure 4C). The distribution of
myelin thicknesses was unchanged in mutant versuscontrol samples at P7 (p > 0.1, K-S test). However, the
G-ratio (total diameter including myelin/axon diameter)
was also significantly decreased (0.67 6 0.10 in control
versus 0.63 6 0.13 in mutant mice, p < 0.001, K-S test),
consistent with normal myelination and reduced axon
diameter. This suggests that mild axonal atrophy pre-
dominantly affecting larger axons may already be pres-
ent at P7.
By P35, the mean axonal diameter of myelinated fibers
was further decreased in mutant nerves (Figures 4D–4H).
A complete absence of large-diameter axons was evi-
dent. An additional eightGarsNmf249/+and sixGars+/+ sci-
atic nerves, ages P21–P37, were examined by Toluidine
blue histology and were qualitatively like those of the P35
mice quantified by TEM for Figure 4F, with large-diame-
ter axons clearly missing from all theGarsNmf249/+nerves.
Degenerating axons were also observed in nerves from
GarsNmf249/+ mice (Figures 4I and 4J), with 18 degenerat-
ing axonal profiles observed in the 448 mutant axons ex-
amined by TEM, while no such profiles were seen in 223
wild-type axons. Degenerating axons were defined as
those with no visible axoplasm, surrounded by an intact
myelin sheath and basal lamina. The preferential loss of
large axons is consistent with the altered muscle con-
traction kinetics (Figure S2), as these axons innervate
large, fast-contracting motor units.
The remaining axons were still myelinated, and no ev-
idence of demyelination, such as ‘‘onion bulb’’ pathol-
ogy or thinly myelinated axons (Suter and Scherer,
2003), was observed. The G-ratio determined from P35
TEM images collected above actually decreased
(0.57 6 0.11 control versus 0.50 6 0.12 mutant, p <
0.001, K-S test). This can be explained by the degenera-
tion of large-diameter axons while maintaining a rela-
tively normal range of myelin thicknesses (Figure 4F)
and is inconsistent with a demyelinating neuropathy.
Internodal distances (INDs) were not significantly re-
duced in mutant mice (519 6 36 versus 475 6 41 mm
Dominant Neuropathy in Active GlyRS Mutant Mice
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Axons without Defects in Myelination
At P7, sciatic nerves from Gars+/+ mice (A)
and GarsNmf249/+ mice (B) show no obvious
pathology. (C) However, the distribution of
axonal diameters is slightly but significantly
shifted in the mutant nerves, with a population
of small, presumably atrophic axons already
evident at this age (circled in Figure 5C).
Myelin thickness is not significantly different
(p > 0.1, K-S test). A total of 516 axons from
four GarsNmf249/+ mice and 392 axons from
three Gars+/+ mice were measured by trans-
mission electron microscopy (TEM) in these
analyses. At P35, control mice have large-di-
ameter axons in the sciatic nerve ([D], circled
in [F]), while GarsNmf249/+ mice completely
lack large-diameter axons (E). (F) The mean
axonal diameter is decreased from 3.13 6
1.27 in Gars+/+ mice to 1.57 6 0.54 in
GarsNmf249/+ mice (p = 0.0002, K-S test). The
maximum size of axons is reduced from 7.1
to 3.8 mm, and consistent with the loss of
large-diameter axons, the distribution of my-
elin thicknesses is reduced in mutant mice
from a mean of 0.84 6 0.36 to 0.69 6 0.28
(p < 0.001, K-S test, 223 axons from three
P35 Gars+/+ mice and 448 axons from three
P35 GarsNmf249/+ mice were analyzed by
TEM for [F]). TEM analysis of Gars+/+ (G) and
GarsNmf249/+ (H) sciatic nerves revealed no
hallmarks of demyelination/remyelination.
No degenerating axons were seen in control
mice (I), while axon profiles enwrapped by
a single Schwann Cell and basal lamina, but
lacking clear axoplasm, were observed in
GarsNmf249/+ nerves (arrowheads in [H] and
[J]). Scale bar in (E) is 30 mm for (A), (B), (D),
and (E), and bar in (I) is 6.5 mm for (G) and
(H) and 1.5 mm for (I) and (J).for Gars+/+ and GarsNmf249/+ mice, respectively, p = 0.24,
n = 3 mice, 234 INDs measured for Gars+/+ mice, and 3
mice, 344 INDs measured for GarsNmf249/+ mice, age
P35). A trend toward smaller INDs is anticipated with
the loss of large-diameter axons. Thus the absence of
fast-conducting, large-diameter axons from peripheral
nerves explains the reduced NCV, with no evidence for
contribution from demyelination or decreased inter-
nodal distances.
Slowly Progressing Sensory and Motor Peripheral
Axon Loss in GarsNmf249/+ Mice
We examined sensory involvement in the mouse model
of CMT2D by counting axons in the motor and sensory
branches of the femoral nerve (Scherer et al., 2005) at
P7–P8 and P32–P35 (n = 1 mutant and control littermate
pair at P7, 2 mutant and control littermate pairs at P8; P7
and P8 numbers were pooled for each genotype). No re-
duction in myelinated axon number was seen at P7–P8
in either motor or sensory nerves (Figures 5A–5E). How-
ever, by P32 a significant decrease in both motor (23%
[p << 0.01]) and sensory (19% [p < 0.01]) axon number
was seen (Figures 5F–5J). Four P32 GarsNmf249/+ mice,
one P32 Gars+/+ littermate, and three P35 C57BL/6J
control mice were analyzed. As in the sciatic nerve, the
axons missing were the largest-diameter fibers, and
the combination of smaller axon diameter and reduced
number resulted in a strikingly smaller nerve. Therefore,the GarsNmf249/+ model of CMT2D has clear sensory
axon involvement. Furthermore, the number of unmy-
elinated axons in control and mutant femoral motor
branchs of the P32 mice was unchanged (331 6 13
and 383 6 91, p = 0.34), suggesting that the myelinated
axons are truly lost and not atrophied or demyelinated.
Most of the affected mice die between 5 and 8 weeks
of age, but, approximately 4% of the animals survive 6
months or more in the B6 genetic background. Little
overt progression in the severity of neuromuscular dys-
function is seen in these mice, even when aged to 1 year.
Quantification of axons in the femoral nerves from 52-
to 61-week-old mice revealed modest but significant
progression in the motor axon loss (an additional 12%
of axons were lost, p < 0.01) with less progression in
axon loss in sensory nerves (an additional 4% loss,
p = 0.056) (Figure 5F). Motor branches from three
GarsNmf249/+ and four Gars+/+ mice and sensory
branches from four GarsNmf249/+ and four Gars+/+ litter-
mates were counted. Thus, most of the axon loss in
the GarsNmf249/+ mice occurs by 1 month of age, and
mice that do not succumb to the initial insult exhibit
only a modest additional decrease in axon number at 1
year.
The axonal phenotype is more pronounced distally.
Examination of the femoral motor nerve and the fifth
lumbar ventral root (L5), both isolated from the same
mice at P34, revealed that the femoral nerve lost 28%
Neuron
720Figure 5. Motor and Sensory Axon Loss
(A) Myelinated axons from the motor and sensory branches of the femoral nerve were counted at P7–P8 in Gars+/+ and GarsNmf249/+ mice. No
significant change in axon number was found in either the sensory or motor branch of the nerve. Like the sciatic, femoral motor nerves from con-
trol (B) and mutant (C) were indistinguishable, as were sensory branches (D and E). However, at P32–P35 a significant decrease in the number of
myelinated sensory and motor axons was found (F). Axons in the motor branch decreased from 5356 8 in control mice to 4106 8 inGarsNmf249/+
mice (p << 0.001). Axons in the sensory branch decreased from 7816 36 in control nerves to 6366 20 inGarsNmf249/+ nerves (p < 0.001). As in the
sciatic nerve, large-diameter axons were lost (G–J). In mice greater than 1 year of age (F), significant additional loss of axons was evident in the
motor branch (3616 6, p < 0.001), but not in the sensory branch (6116 7, p = 0.06). No differences in axon number at 1 year of age were seen in
control nerves (5396 7 motor and 7936 10 sensory). Scale bar in (J) is 50 mm for (B)–(E) and (G)–(J). Insets are 303 22.5 mm. The values in (A) and
(F) are means of axon number in each nerve 6 SD.of its myelinated axons (5306 16 in control versus 3826
30 in mutant samples, n = 3 mice of each genotype),
while there was no change in the axon number in the
L5 root (9636 130 in control versus 10206 28 in mutant
roots). Similarly, no pathology was evident in the spinal
cord of mutant animals (data not shown, n = 5 examined
at P24 and n = 4 examined at P36–P37). Thus the neu-
ropathy progresses from distal to proximal, with a loss
of axons in distal nerve branches and no loss of axons
in ventral roots, or death of cell bodies in the spinal cord.
Muscles from the older mice showed evidence of
atrophy and long-term denervation and reinnervation
(Figure S3). These changes included fibrosis and hyper-
trophic, atrophic, and regenerated muscle fibers. Mus-
cle fibers were also lost, and grouping of muscle fiber
types caused by denervation and compensatory termi-
nal sprouting of the remaining motor neurons was evi-
dent in the mutant muscles.
To test whether a hybrid genetic background could
improve survival, a B6 3 BALB F1 mouse was mated
to CAST/EiJ. The resulting hybrids carrying the
GarsNmf249 mutation were still overtly affected with
a similar age of onset. However, more mice survived be-
yond 8 weeks (>90%), and these mice could be bred by
standard practices. Interestingly, no GarsNmf249/Nmf249
homozygous mice were identified at birth, suggestingthey are embryonic lethal (20 offspring genotyped from
4 litters, c2 value = 0.035).
GarsNmf249 Is Not a Loss-of-Function Allele
The more severe phenotype (embryonic lethality) of ho-
mozygous GarsNmf249/Nmf249 mice is consistent with the
anticipated loss-of-function phenotype but could also
be explained by an increased dose of a toxic gain-
of-function protein. Furthermore, the P278KY mutation
is near one human allele (G240R, see Figure 1D) immedi-
ately before domain 2 of the catalytic portion of the pro-
tein. However, other reported human alleles are spread
across the peptide sequence (E71G, L129P, D500N,
and G526R) (Antonellis et al., 2003; Del Bo et al., 2006).
These amino acids do not cluster to a functional domain
such as the catalytic or anticodon recognition domains,
raising the question of whether the disease is correlated
with changes in GlyRS enzyme activity.
To address the genetic mechanism of theGarsNmf249/+
mutation, we examined an unambiguous loss-of-
function allele. This allele is the result of a gene-trap in-
sertion (XM256) in the second intron of the 17 exon Gars
gene (Skarnes et al., 1995). In mRNA samples isolated
from brain and kidney, GarsXM256/+ mice had expression
levels of 59% and 54%, respectively, compared to con-
trols (n = 3 each genotype, littermates, age P44). Thus
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a Loss-of-Function Mutation
The genetic mechanism of dominant Gars
mutations was examined by comparison to
a gene-trap allele of Gars (GarsXM256) that in-
tercepts transcripts after exon 2. (A) The
XM256 insertion effectively reduced mRNA
levels by Northern analysis using a cDNA
probe that is downstream of exon 2. Ex-
pression of Gars was quantified using phos-
phor-imager densitometry and compared
hybridization intensity of a standard (RPL29)
applied to the same blots; representative ad-
jacent lanes are shown. Despite the loss of
Gars mRNA, the sciatic nerves of Gars+/+ lit-
termate control (B) and GarsXM256/+ mice (C)
are indistinguishable, with no loss of large-di-
ameter axons and no evidence of degenerat-
ing axons in the gene-trap mice. (D) The fem-
oral nerves showed no decrease in axon
number in either the sensory or motor branch,
and the neuromuscular junctions of control
(E) and GarsXM256/+ mice (F) were indistin-
guishable, indicating that the abnormal post-
synaptic differentiation observed in the
GarsNmf249/+ mice was not present in the
gene-trap mice. No denervated or partially
denervated junctions were seen. All analyses
in (B)–(G) were done on three GarsXM256/+
mice and three Gars+/+ littermates, age P44.
(G) Mutant and wild-type recombinant GlyRS
protein was assayed for initial rates of amino-
acylation (pmoles Gly-tRNA/min 6 SD for
each enzyme concentration tested, wt [cir-
cles], or P234KY [triangles]). No decrease in
enzymatic activity was seen in the mutant
form of the protein. Each point represents
the mean of six trials. The scale bar in (C) rep-
resents 30 mm, the bar in (F) represents 11 mm.
The values in (B) are reported 6 SD.the gene-trap insertion effectively reduced Gars expres-
sion (Figure 6A). These results were confirmed by quan-
titative PCR analysis, which indicated a 1.8 6 0.4-fold
reduction in Gars expression (data not shown, see
Experimental Procedures). Therefore, this allele is a
loss-of-function allele at the mRNA level. Furthermore,
the gene-trap allele is also embryonic lethal, with no
GarsXM256/XM256 homozygotes evident at birth in 18
pups from five litters (c2 = 0.04), again consistent with
the anticipated loss-of-function phenotype for this
gene and suggesting that little if any wild-type splicing
was still present.
Despite the loss of Gars expression, this allele
showed no dominant phenotype. The sciatic nerves of
GarsXM256/+ mice contained large-diameter axons and
were histologically indistinguishable from littermate
controls (Figures 6B and 6C). Similarly, there was no
loss of axons in either the motor or sensory branch of
the femoral nerve (Figure 6D), and neuromuscular junc-
tions had mature morphology with no evidence of
denervated synapses (Figures 6E and 6F). Nerve
conduction velocities in GarXM256/+ mice were not differ-
ent than those in wild-type littermates (30.4 6 3.8 m/s
versus 30.6 6 2.7 m/s in Gars+/+ and GarXM256/+ mice,
respectively, n = 3 mice each genotype, average age
P35 6 8.7), and the NMJs in the lateral gastrocnemius
showed complete occupancy (98.5% 6 1.3% fullyinnervated NMJs, n = 4 GarXM256/+ mice, average age
P34 6 7.5).
To determine whether the P to KY mutation affected
GlyRS enzymatic activity, the change was introduced
in the human GARS coding sequence (Figure S4).
Wild-type and P234KY human GlyRS were overex-
pressed in E. coli, purified to near-homogeneity, and
assayed for initial rates of aminoacylation (time points
during the first 4 min of the reaction) at enzyme concen-
trations of 1, 2, 5, 10, 15, and 25 nM. For both wild-type
and mutant enzyme, the initial rates showed a strictly lin-
ear dependence on total enzyme concentration, with
both sets of initial rates scattering about the same line
(Figure 6G). Because the initial rates for both enzymes
were the same over a 25-fold range of concentration,
we conclude that the P234KY substitution does not dis-
rupt the active site and that the mutant enzyme is fully
active. This finding suggests that the mutant phenotype
does not arise from haplo-insufficiency or a dominant-
negative pathogenic mechanism.
Despite the normal activity of the P234KY GlyRS, the
GarsNmf249 allele could still be causing a loss-of-function
phenotype through mechanisms such as protein insta-
bility or reduced efficiency of folding. Interestingly,
when GarsNmf249/+ and GarsXM256/+ mice were mated,
no compound heterozygous offspring were identified
at birth in 28 mice from five litters (c2 value = 0.02).
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tion in Nmf249 or it could indicate that the wild-type al-
lele has some ability to compensate for or compete
with the mutant protein in a pathogenic gain of function.
However, for a loss-of-function or dominant-negative
mechanism to account for the dominant CMT2D-like
phenotype, the GlyRS activity in GarsNmf249/+ would
have to be reduced significantly more than in
GarsXM256/+, which showed no phenotype. To assess
this, GlyRS activity was assayed directly from brain ho-
mogenates of Gars+/+, GarsNmf249/+, and GarsXM256/+
mice. The activity of alanyl-tRNA synthetase (AlaRS)
was used as an internal standard for each sample, and
the ratios of GlyRS to AlaRS activity were determined
and normalized to the control values, defined as 100%.
Ratios of GlyRS/AlaRS activities of 100 6 49, 63 6 14,
and 29 6 5 were obtained for Gars+/+, GarsNmf249/+,
and GarsXM256/+, respectively. While GarsNmf249/+ tissue
showed only an insignificant decrease in activity com-
pared to control (p = 0.14), it retained significantly
more activity than GarsXM256/+ tissue (p = 0.006). The as-
say was performed with n = 5 GarsNmf249/+ mice, n = 3
GarsXM256/+ mice, and n = 4 control mice.
Because the GarsXM256 mice represent a loss-of-
function allele, have less GlyRS activity as heterozy-
gotes than GarsNmf249/+ mice, and have no dominant
phenotype and because the recombinant P234KY en-
zyme retains normal kinetics and activity, we conclude
that the GarsNmf249 allele causes peripheral neurop-
athy because the mutant GlyRS protein assumes a
pathogenic function, and not because of a loss of GlyRS
activity.
Discussion
A Mouse Model of CMT2D
We have quantitatively analyzed the first animal model
of CMT2D. As in the human patients, the mutation is
dominant and causes an amino acid substitution, not
a truncation or null allele. The mice demonstrate clear
distal motor neuropathy with defects in synaptic con-
nectivity at the NMJ and denervation pathology in the
muscle. In addition, large-diameter axons are lost from
both motor and sensory peripheral nerves, causing re-
duced nerve conduction velocities without contributing
defects in myelination or internodal distances. Further-
more, the mice show distally accentuated and length-
dependent axon loss, with no observed pathology in
the spinal cord. Based on these genetic and phenotypic
analyses, this mutation creates a valid model of CMT2D
for use in future mechanistic studies.
The nerve conduction velocities in the mouse are de-
creased dramatically (60%), while human patients often
show no decrease in conduction velocity (Ionasescu
et al., 1996), or only a modest decrease in the lower
limbs, with values in the peroneal nerve as low as 34.5
m/s (Del Bo et al., 2006) or 37 m/s (Sivakumar et al.,
2005) in select patients. In this regard, the mouse pheno-
type is more severe than the human disease, but
whether that represents a more profound loss of large-
diameter axons or whether the analysis of the mice
was done at a later stage of the disease is unclear.
In the mouse model, sensory nerves are also clearly
affected, although this remains ambiguous in the humandisease. CMT2D and SMA-DV are allelic (Sambuughin
et al., 1998), but the clinical diagnosis of CMT2D de-
pends on the presence of sensory symptoms. In the
five pedigrees initially identified, three presented with
purely motor SMA-DV, one with CMT2D, and one was
ambiguous (Dubourg et al., 2006; Sivakumar et al.,
2005). A sixth pedigree recently reported also has vari-
able sensory involvement (Del Bo et al., 2006). However,
even in the mouse, sensory-axon loss had a milder initial
severity and less progression than motor-axon loss. If
this is also the case in humans, it may contribute to dis-
crepancies in the clinical diagnosis of SMA-DV and
CMT2D.
Genetic Background and Allelic Variability
The differences in clinical presentation in CMT2D pa-
tients suggest allelic variability in the phenotype. In ad-
dition, variability in symptoms such as sensory involve-
ment and age of onset even within pedigrees suggests
possible modifier loci in the genetic background may
also influence the phenotype. Results in the mouse sup-
port both the influence of genetic background and allelic
variability. GarsNmf249/+ mice in a mixed B6/BALB/CAST
background exhibit better survival than inbred B6
GarsNmf249 mice, although they still show overt neuro-
muscular dysfunction with a similar age of onset. It re-
mains to be determined whether this suppression is
caused by a few specific loci or can be attributed to gen-
eral ‘‘hybrid vigor.’’
In addition to the P278KY mutation of GarsNmf249 de-
scribed here, a second allele of Gars that also causes
dominant neuromuscular dysfunction in mice has been
identified in the Harwell Mutagenesis Program in the
U.K. (Elizabeth Fisher, personal communication). This
new allele has a milder phenotype than the GarsNmf249
allele, with no early lethality and detection of mutants
by grip strength assays, since the locomotor abnormal-
ities are more subtle. This allele is also sensitive to ge-
netic background, producing live-born homozygous
pups that survive for days to weeks in some back-
grounds while causing embryonic lethality in others.
Thus, though the phenotype of the mouse allele de-
scribed here is in some ways more severe than the hu-
man disease, results in other genetic backgrounds and
in other alleles indicate that mouse Gars mutations will
provide important mechanistic and phenotypic insights
into CMT2D pathogenesis.
A Pathogenic Function for the Mutant Protein
The comparable activity of mutant and wild-type GlyRS
proteins makes a loss-of-function mechanism through
impaired enzymatic activity unlikely. Other defects,
such as in vivo instability of mutant homo- or hetero-
dimers or decreased efficiency of protein folding, may
account for the slight reduction in GlyRS activity ob-
served in tissue extracts from GarsNmf249/+ mice com-
pared to controls, though the observed effect is not sta-
tistically significant. However, the lack of a dominant
phenotype in the XM256 gene-trap allele, despite signif-
icantly lower GlyRS activity in GarsXM256/+ tissue ho-
mogenates compared to GarsNmf249/+ homogenates,
eliminates the possibility that the disease is caused by
a loss of the canonical GlyRS activity or by a domi-
nant-negative activity of the mutant protein. These
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caused by a novel pathogenic function of the mutant
protein.
In this regard, Gars/CMT2D is analogous to diseases
like amyotropic lateral sclerosis (ALS), caused by muta-
tions in SOD1. In each, the loss of peripheral neurons
with large-diameter axons results from mutations in
a ubiquitously expressed enzyme, but enzymatic activ-
ity is not correlated with phenotype (Bruijn et al., 2004).
Furthermore, in both ALS and CMT2D, the disease ap-
pears to require the expression of mutant protein, and
not to be caused by a null-allele. Genetically, SOD1 mu-
tations are closer to true gain-of-function alleles, where
the dosage of the wild-type protein does little to alter the
phenotype (Bruijn et al., 1998), while the GarsNmf249 al-
lele fails to complement a loss-of-function allele. How-
ever, some of this difference may be caused by the es-
sential activity of GlyRS, while SOD1 is dispensable.
CMT2D and ALS models also show phenotypic similar-
ities, in that NMJs are affected early in the disease
(Fischer et al., 2004; Pun et al., 2006), the severity is
length dependent and more severe in distal axons, and
large-diameter axons are primarily affected. However,
CMT2D has no known central nervous system pathol-
ogy, while ALS also affects upper motor neurons and
shows eventual loss of motor neuron cell bodies in the
spinal cord. Intriguingly, two mutant forms of SOD1
that cause ALS in humans and in transgenic mice also
bind lysyl-tRNA synthetase (LysRS), while wild-type
SOD1 does not, suggesting that allele-specific interac-
tions with the translational machinery may contribute
to the disease (Kunst et al., 1997). However, as in
GARS, the mutations in SOD1 that cause ALS are scat-
tered throughout the enzyme, and only the G85R and
G93A alleles have been tested for their interaction with
LysRS.
Noncanonical Functions of Aminoacyl Transferases
The charging of glycine onto its tRNAs is essential for
translation and is the only known function of the GlyRS
enzyme. However, noncanonical functions have been
demonstrated for other tRNA synthetases (Lee et al.,
2004). For instance, a natural, alternative splice frag-
ment of human tryptophanyl tRNA synthetase and a sim-
ilar natural proteolytic fragment inhibit angiogenesis
through interactions with VE-cadherin (Tzima et al.,
2005; Wakasugi et al., 2002). Human tyrosyl-tRNA syn-
thetase is naturally split into two active cytokines that
regulate the inflammatory response (Wakasugi and
Schimmel, 1999). In this instance, two distinct domains
of the protein are important for cytokine functions, sug-
gesting at least the possibility for mutations in scattered
regions that could be associated with pathologies. Fur-
thermore, glutamyl-prolyl tRNA synthetase is part of
a multisynthetase complex which, under the influence
of g-interferon, translocates to the g-interferon-acti-
vated inhibitor of translation complex (GAIT), where it
causes gene-specific translational silencing of a proin-
flammatory protein (Sampath et al., 2004).
Mutations in glycyl tRNA synthetase and the disease
CMT2D are analogous to other degenerative neuropa-
thies, suggesting common pathogenic pathways. For
example, mutations in human tyrosyl-tRNA synthetase
were recently shown to cause dominant intermediateCMT type C (Jordanova et al., 2006). However, in this in-
stance the authors reported that the CMT phenotype
correlated with a reduction in enzyme activity and
a dominant-negative role for the mutant protein, sug-
gesting that a defect in protein synthesis may specifi-
cally affect neurons. In contrast, a loss-of-function allele
of Gars showed no dominant phenotype despite signif-
icantly lower GlyRS activity levels than in the Nmf249 al-
lele. Furthermore, the P234KY mutant enzyme studied
here showed no loss of aminoacylation activity. (In other
work, we found at least one example encoded by
a known CMT-associated specific mutant allele of
human GARS that also had normal enzyme activity
[L.A.N. and P.S., unpublished data].) Because one
gene encodes both the cytosolic and mitochondrial
forms of the protein in mammals (Mudge et al., 1998;
Turner et al., 2000), pathogenesis may be caused by mi-
tochondrial dysfunction. However, the loss-of-function
gene-trap allele suggests that the CMT phenotype is
not associated with decreased GlyRS activity needed
for protein synthesis in the mitochondria or cytoplasm.
In addition, the CMT phenotype caused by mutations
in TyrRS is associated with the cytoplasmic, not the mi-
tochondrial, enzyme (Jordanova et al., 2006), which in
the case of TyrRS is encoded by two distinct genes.
Understanding the cell autonomy, the dysfunctional
subcellular compartment, and the molecular interac-
tions of the mutant GlyRS protein will be essential for un-
derstanding the pathogenesis of CMT2D and offers the
possibility of extrapolating these findings to other neu-
rodegenerative conditions that also affect this popula-
tion of neurons.
Experimental Procedures
Mice
The Nmf249 mutation arose in the Neuroscience Mutagenesis Facil-
ity at The Jackson Laboratory in 2004. The mutation was originally
isolated on an inbred C57BL/6J (B6) background; all experiments
described used mice with this genetic background. As the mutation
is dominant and lethal before mice can be effectively bred, the strain
is maintained by ovary transplantation. Ovaries are surgically re-
moved from 3- to 4-week-old affected mice and implanted into
NOD.CB17-Prkdcscid/J recipient females. The recipient females are
then bred by standard practices.
Ages and numbers of mice used in histological, physiological, im-
munocytochemical, and electron microscopy studies are stated in
the text and figure legends. Controls were most often unaffected lit-
termates, though in some studies on femoral nerves, conduction ve-
locities, and enzyme activities, strain- (C57BL/6J) and age-matched
controls were used.
All animal procedures were carried out using protocols approved
by The Jackson Laboratory Animal Care and Use Committee and in
accordance with the NIH Guide for the Care and Use of Laboratory
Animals.
Genetic Mapping
The Nmf249 mutation was mapped to chromosome 6 by breeding
affected B6 mice (by ovary transplant) to BALB/cByJ (BALB) males
to create B6 3 BALB F1 mice. Affected mice from this cross were
then backcrossed (again by ovary transplant) to BALB males to cre-
ate a segregating N2 population. These animals were scored for
overt signs of neuromuscular dysfunction, and a whole genome
scan using 98 microsatellite markers (DMitmarkers) spaced approx-
imately every 10 cM across the 19 autosomes was performed on 16
affected and 11 unaffected mice; complete linkage with D6Mit188 in
the central portion of chromosome 6 was found. The genetic interval
was narrowed by recombination mapping on an additional 76 N2
mice using additional chromosome 6 MIT markers (D6Mit183
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D6Mit188, D6Mit361, D6Mit132).
Sequence Analysis
The Gars open reading frame was amplified from first-strand cDNA
generated from brain RNA from an affected Nmf249 mouse. The
sequence was amplified in three overlapping segments using the
following primer pairs: 1F to 1R (CTAGGCGGCGTGCTCATG to
CCCAATGAAGGTCTGGAAC), 2F to 2R (CTCCCACCACTGGCAAT
GAC to CTCACTCAGCAGCAGCTCC), and 3F to 3R (GCTAGTGCTG
GAGTATCTC to CGTCCCTGGATGCAGTCAC). The PCR products
were sequenced directly and compared to the C57BL/6J sequence
from the mouse genome project (http://www.Ensembl.org. NCBI
build m33 mouse assembly) and to the sequence obtained from an
unaffected B6 mouse from the same colony. An accurate mouse
Gars cDNA sequence is available with accession number NM
180678 (Lang et al., 1996). Double sequence was found in the
2F-2R PCR product in the Nmf249 cDNA, indicating an insertion or
deletion in this part of the gene. As the mutation is dominant and
heterozygous, the PCR product was subcloned by Topo-TA cloning
(Invitrogen), and individual clones were sequenced to confirm the
sequence change. The same approach was used to confirm the
mutation in the genomic DNA of exon 7 (intron 6F to intron 7R,
GCCTTGTTCTGTAACGTTTGCAC to CAAGTTTACCTTTTGTCACA
GGC). A mutation-specific and wild-type-specific PCR assay was
developed (mutation CCAGGCATATTTCCTCCATATTT, wild-type
CCAGGCATATTTCCTCCAGG, both in combination with intron 6F
above), and affected mice were confirmed to carry the mutation.
Immunofluorescence of NMJs
Immunofluorescence was performed as described (Burgess et al.,
2004; Gautam et al., 1996). For confocal analysis, muscles were fro-
zen in OCT, and 30 mm thick cryostat sections were mounted on
slides and stained to visualize en face junctions. Cocktails of the
following primary antibodies were used to visualize nerves: anti-
neurofilament (rabbit polyclonal (Sigma) or SM 31 monoclonal
(Sternberger Monoclonals), rabbit anti-synaptophysin (Zymed),
and mouse anti-SV2 (DSHB). Alexa Fluor 488-conjugated anti-rabbit
and anti-mouse secondary antibodies (Molecular Probes) were
used. Tetramethylrhodamine-conjugated a-bungarotoxin (Molecu-
lar Probes) was used to visualize acetylcholine receptors on the
muscle cell surface. Images were collected on a Nikon E600 fluores-
cence microscope and SPOT-RT camera or on a Leica NT or SP2
confocal microscope.
Occupancy was determined by examining 100 randomly selected
NMJs in each muscle. Junctions where the nerve completely over-
lapped the AChRs on the muscle were defined as fully occupied,
NMJs with vacant receptor territory were defined as partially occu-
pied, and AChR plaques with no nerve associated were defined as
denervated. In the P7 and P36–P37 mice examined for Figures 2
and S1, nerves were visualized by EYFP fluorescence after mating
to the thy1-EYFP-16 transgenic strain (Feng et al., 2000). In other
cases, nerves were stained with anti-neurofilament as described
above.
Analysis of Gars mRNA Levels
RNA from the brain and kidney of mutant and control mice was poly-
A+ selected, and 2 mg of each mRNA sample was run on a denaturing
gel, blotted, and probed by standard techniques. The Gars 1F-1R
PCR product described above was used as a probe for the blot in
Figure 1, and 2F-2R was used as a probe for the blots in Figure 6.
Loading was standardized by reprobing the blots with a b-actin frag-
ment (Figure 1) or Rpl29 (Figure 6). The hybridization intensity was
quantified using a FujiFilm phosphor imager and the associated
software, and ratios of Gars signal intensity/standard intensity
were determined for each lane. The ratios between mutant and con-
trol samples were compared to calculate a percent reduction. For
example, in the gene-trap analysis, ratios were 0.30 6 0.01 versus
0.50 6 0.05 for the three GarsXM256/+ brain mRNA samples versus
control, and 0.091 6 0.006 versus 0.167 6 0.014 for samples from
the kidney, giving expression levels of 59% and 54%, respectively.
In addition, 5 mg of each total RNA sample prepared above was re-
verse transcribed, and the resulting cDNA was used for quantitative
PCR analysis. RNA samples were treated with RNase-free DNase1before reverse transcribing. Two amplicons were used (forward
1 = GGAGCAGATCCTGGAGATTGACT, reverse 1 = CGGAAGCACTC
TCCGTTCTTC, and forward 2 = GTGAACAAGACGCCCCACAC,
reverse 2 = CCCAGGTAATGTTGCCGTTG) and b-actin was used
as an internal control. Each sample was run in triplicate and aver-
aged for each tissue to represent an n = 1. The difference in amplifi-
cation cycle betweenGars and the actin standard was calculated for
each sample (Amplicon 1 brain DCt = 2.186 0.25 versus 1.486 0.44
for mutant versus control, respectively, p = 0.07, kidneyDCt = 3.506
0.51 versus 2.26 60.25 for mutant versus control, respectively,
p = 0.02. Amplicon 2 brain DCt = 20.42 6 0.07 versus 21.10 6
0.13 for mutant versus control, respectively, p = 0.001, kidney
DCt = 0.566 0.48 versus20.146 0.39 for mutant versus control, re-
spectively, p = 0.12). The difference in cycle number determined
a fold-reduction in Gars RNA expression in the GarsXM256/+ mice
(one cycle = 2-fold change, DDCts = 0.68 and 0.70 for brain and
1.24 and 0.70 for kidney for amplicon 1 and 2, respectively, average =
0.83- or 1.8-fold reduction in Gars mRNA). In all samples in both kid-
ney and brain, the GarsXM256/+ samples showed lower expression of
Gars than controls. Both amplicons were downstream of exon 2.
Nerve Histology and Electron Microscopy
Tissue was fixed by transcardial perfusion with 2% glutaraldehyde/
2% paraformaldehyde in 0.1 M cacodylate buffer. Sciatic and femo-
ral nerves were dissected free and postfixed overnight in the same
fixative. Tissue was then processed for plastic embedding and
transmission electron microscopy (TEM) by standard procedures.
0.5 mm sections were also stained with Toluidine blue and examined
by light microscopy. TEM images were collected on a Jeol 1230 mi-
croscope. Axon diameters of P35 mice were determined from five
nonoverlapping 60003 fields from each of three mutant and three lit-
termate control samples. In P7 samples, five 60003 fields from each
of four mutant and three control mice were analyzed. Distances were
determined using the associated software. For counts of axons, left
and right nerves were taken whenever possible, and counts were av-
eraged so that each n represents one mouse and the average count
of the left and right nerve. The total number of myelinated axons in
each nerve was counted using light microscopy on Toluidine blue-
stained plastic sections.
Muscle Contractile Experiments
Experimental procedures for in situ muscle recordings were adap-
ted from those used previously in the rat (Seburn and Gardiner,
1995). Anesthesia was induced (tribromoethanol 0.2 mg/10 g), and
the mouse was intubated and ventilated with a mix of oxygen and
isoflurane (0.5%–1.5%) to maintain anesthesia. CO2 was maintained
at 30–40 mm Hg, and body temperature was maintained at 37C 6
1C.
A dorsal incision through the skin and hamstrings of the leg ex-
posed the triceps surae. The achilles tendon was cut and tied with
4.0 surgical silk to a force transducer (Fort 100, WPI). The sciatic
nerve was contacted by a bipolar stimulating electrode. Sciatic
nerve branches except the MG nerve were transected and crushed
proximal to the stimulating electrode. The hindlimb was clamped at
the femur and maintained at 37C 6 1C. A unipolar silver ball elec-
trode was placed in contact with the MG muscle and attached to an
amplifier for electromyogram (EMG) recordings.
Stimulus voltage was increased until twitch amplitude no longer
increased, and then set 50% higher to ensure maximal activation.
Muscle length was adjusted to obtain maximal twitch force.
An isometric muscle twitch (Pt) was recorded following a single
stimulus (0.02 ms square pulse) delivered to the sciatic nerve. Te-
tanic contractions were recorded in response to pulse trains deliv-
ered at frequencies of 10, 30, 50, 80, 100, and 150 hertz (0.02 ms
pulse duration, 1.2 s), with 2 min of recovery between each stimulus.
Mice were removed, and nerve conduction distance was measured,
and the MG muscle was removed and weighed.
Measures of peak twitch force, twitch time-to-peak (ms) (TPT),
and half-relaxation time (ms) (1/2RT) were derived from the isometric
twitch trace. The peak amplitude for each tetanic frequency was
measured. All force measures were normalized for muscle weight.
Electromyograms were rectified and integrated for analysis.
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In separate experiments, conduction velocity of sciatic axons was
calculated by measuring the latency of compound motor action po-
tentials recorded in the muscle of the left rear paw (Occhi et al.,
2005). Mice were anesthetized with isofluorane (1%–1.5%) and
placed on a thermostatically regulated heating pad to maintain nor-
mal body temperature. Action potentials were produced by subcu-
taneous stimulation at two separate sites: proximal stimulation at
the sciatic notch and by a second pair of needle electrodes placed
distally at the ankle. For recording, a needle electrode was inserted
in the center of the paw (active) and a second electrode (reference)
was placed in the skin between the first and second digits. Conduc-
tion velocity was calculated as [(proximal latency 2 distal latency)/
conduction distance]. Three animals of each genotype were tested.
Statistical Analysis
A two-tailed t test was used to compare between groups unless oth-
erwise noted. The nonparametric Kolmogorov-Smirnov test (K-S
test) was used for comparing the distributions of axon morphomet-
rics, and significance was confirmed by nested-ANOVA. A probabil-
ity value of%0.05 was used as a limit for declaring statistical signif-
icance. All n values used are based on the number of animals in each
group. All values are reported 6 standard deviations.
GlyRS Protein Expression and Purification
For expression and purification, sequence-verified human GlyRS
cDNA was obtained (Invitrogen), and the P234KY mutation was in-
troduced via site-directed mutagenesis of the wild-type form using
the QuickChange site-directed mutagenesis kit (Stratagene, La
Jolla, CA) and the following oligonucleotides as primers: P234KY
F, 50-CTTAATGTTCAAGACTTTCATTGGGAAATATGGAGGAAACAT
GCCTGGGTACTTG-30 and P234KY R, 50-CAAGTACCCAGGCATGT
TTCCTCCATATTTCCCAATGAAAGTCTTGAACATTAAG-30. Both the
wt and P234KY GlyRS forms were subcloned into pET21a(+) (EMD
Biosciences, Inc., Novagen, San Diego, CA) to generate a C-terminal
His-tagged form. Both forms of GlyRS were overexpressed in E. coli
BL21-CodonPlus(DE3)-RIL cells (Stratagene, La Jolla, CA). Cells
bearing the GlyRS plasmids were grown overnight to saturation, af-
ter which 2.5 ml of culture was used to inoculate 2.5 l of LB medium
containing 100 mg/ml of ampicillin. Cultures were incubated at 37C
shaking until they reached an OD600 of 0.6, at which time IPTG
(Roche, Indianapolis, IN) was added to a final concentration of
200 mM to induce expression of GlyRS. After briefly cooling on ice,
cells were incubated for an additional 5 hr in a 30C incubator with
constant shaking. Cells were harvested by centrifugation, resus-
pended in lysis buffer containing 50 mM Tris-HCl (pH 8.0), 300 mM
NaCl, 25 mM imidazole, 10 mM b-mercaptoethanol, and EDTA-free
protease inhibitor cocktail tablets (Roche, Indianapolis, IN). GlyRS
proteins were purified under native conditions, bound to a nickel-
nitrilotriacetic acid (Ni-NTA) affinity resin (Qiagen, Valencia, CA),
washed with lysis buffer, and eluted on a gradient with lysis buffer
supplemented with 25–250 mM imidazole. Fractions of the highest
purity were pooled, concentrated in a Centriprep YM-30 (Millipore,
Bedford, MA), and diluted in 50% glycerol with 2 mM DTT for storage
at 220C. Concentrations were determined by the Bradford assay
(BioRad, Hercules, CA) followed by active site titration.
Aminoacylation Assays
Aminoacylation assays were performed at 37C in a reaction mixture
containing 100 mM HEPES (pH 7.5), 20 mM KCl, 2 mM ATP, 4 mM
MgCl2, 2 mM DTT, 20 mM L-glycine, 4 mM [
3H-L-glycine], 100 mM
bulk calf liver tRNA (EMD Biosciences, Inc., Novagen, San Diego,
CA), and 1–25 nM wild-type or P234KY GlyRS. Reactions were initi-
ated by addition of reaction mixture and tRNA to the enzyme. Ali-
quots were removed at appropriate time intervals, spotted onto tri-
chloroacetic acid-soaked filter pads, washed, and measured by
scintillation counting (Schreier and Schimmel, 1972). Radioactivity
measurements from an enzyme-free experiment were subtracted
from all experimental data. Each assay consists of six replica trials;
assays were performed twice using independently prepared re-
combinant protein with similar results.Enzyme Activity Assays from Tissue Homogenates
Brains from five GarsNmf249/+, three GarsXM256/+, and four Gars+/+
mice, P28–P30, were removed and flash-frozen in liquid nitrogen.
Homogenates were prepared and cytosolic fractions obtained by
spinning lysates at 100,000 3 g. Aliquots were flash-frozen to avoid
freeze/thaw-associated problems. Each assay was performed on
30 mg of total protein, and each sample was assayed in duplicate
with three individual data points taken for each assay. Homogenates
were assayed for both GlyRS activity and AlaRS activity, which
served as an internal standard for the sample. The ratio of these ac-
tivities for each animal was analyzed. Assays were performed as de-
scribed for recombinant protein with the following modifications:
300 mM bulk calf liver tRNA, 12 mM [3H]-L-glycine or 5 mM [3H]-
L-alanine, and 1 unit of RNasin RNase Inhibitor (Promega). TCA
washes were supplemented with 100 mM L-glycine or D,L-alanine.
Identification of Gene-Trap Mice
The XM256 gene-trap allele was obtained from BayGenomics (bay-
genomics.ucsf.edu). The insertion in the second exon of Gars was
confirmed by RT-PCR from the embryonic stem cells. The insertion
site was identified as being 519 bp downstream of exon 2 in the sec-
ond intron of Gars by PCR from forward primers in the intron and re-
verse primers in the b-geo construct and sequencing the resulting
amplification product. Any transcript generated from the gene-trap
chromosome should not encode more than the first 97 amino acids
of GlyRS and would be a fusion ofGars and the b-geo insertion. Mice
were generated from the ES cells by blastocyst injection. The chime-
ric mice were bred to C57BL/6J mice to generate F1 mice carrying
the XM256 insertion. All analysis was performed in these mice and
littermate controls not carrying the insertion.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/51/6/715/DC1/.
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